These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 27982602)

  • 41. High-density lipoprotein-biomimetic nanocarriers for glioblastoma-targeting delivery: the effect of shape.
    Huang JL; Jiang G; Song QX; Gu X; Song HH; Wang XL; Jiang D; Kang T; Feng XY; Jiang XG; Chen HZ; Gao XL
    Pharmazie; 2016 Dec; 71(12):709-714. PubMed ID: 29441999
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recombinant lipoproteins reinforce cytotoxicity of doxorubicin to hepatocellular carcinoma.
    Wang B; Yuan Y; Han L; Ye L; Shi X; Feng M
    J Drug Target; 2014 Jan; 22(1):76-85. PubMed ID: 24093636
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment.
    Feng T; Tian H; Xu C; Lin L; Xie Z; Lam MH; Liang H; Chen X
    Eur J Pharm Biopharm; 2014 Nov; 88(3):1086-93. PubMed ID: 25305583
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Zwitterionic nanoparticles constructed with well-defined reduction-responsive shell and pH-sensitive core for "spatiotemporally pinpointed" drug delivery.
    Huang P; Liu J; Wang W; Li C; Zhou J; Wang X; Deng L; Kong D; Liu J; Dong A
    ACS Appl Mater Interfaces; 2014 Aug; 6(16):14631-43. PubMed ID: 25100635
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-tumor efficiency of paclitaxel and DNA when co-delivered by pH responsive ligand modified nanocarriers for breast cancer treatment.
    Yu D; Li W; Zhang Y; Zhang B
    Biomed Pharmacother; 2016 Oct; 83():1428-1435. PubMed ID: 27592131
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Superparamagnetic reconstituted high-density lipoprotein nanocarriers for magnetically guided drug delivery.
    Sabnis S; Sabnis NA; Raut S; Lacko AG
    Int J Nanomedicine; 2017; 12():1453-1464. PubMed ID: 28260891
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Folate-modified poly(2-ethyl-2-oxazoline) as hydrophilic corona in polymeric micelles for enhanced intracellular doxorubicin delivery.
    Qiu LY; Yan L; Zhang L; Jin YM; Zhao QH
    Int J Pharm; 2013 Nov; 456(2):315-24. PubMed ID: 24016742
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma.
    Yuan M; Qiu Y; Zhang L; Gao H; He Q
    Drug Deliv; 2016 May; 23(4):1171-83. PubMed ID: 26036724
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synchronized Codelivery of Combination Chemotherapies Intratumorally Using a Lipidic Lyotropic Liquid Crystal System.
    Saklani R; Yadav PK; Tiwari AK; Gawali SL; Hassan PA; Yadav K; Mugale MN; Kalleti N; Rath SK; Mishra DP; Dierking I; Chourasia MK
    ACS Appl Mater Interfaces; 2024 Jun; 16(22):29098-29111. PubMed ID: 38780083
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor targeting effects of a novel modified paclitaxel-loaded discoidal mimic high density lipoproteins.
    Wang J; Jia J; Liu J; He H; Zhang W; Li Z
    Drug Deliv; 2013 Nov; 20(8):356-63. PubMed ID: 24079327
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor-targeted delivery of paclitaxel using low density lipoprotein-mimetic solid lipid nanoparticles.
    Kim JH; Kim Y; Bae KH; Park TG; Lee JH; Park K
    Mol Pharm; 2015 Apr; 12(4):1230-41. PubMed ID: 25686010
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier.
    Mooberry LK; Nair M; Paranjape S; McConathy WJ; Lacko AG
    J Drug Target; 2010 Jan; 18(1):53-8. PubMed ID: 19637935
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs.
    Zhang L; Yao J; Zhou J; Wang T; Zhang Q
    Int J Pharm; 2013 Jan; 441(1-2):654-64. PubMed ID: 23117024
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synergistic Combination of Sodium Aescinate-Stabilized, Polymer-Free, Twin-Like Nanoparticles to Reverse Paclitaxel Resistance.
    Li J; Zheng L; Wang R; Sun D; Liang S; Wu J; Liu Y; Tian X; Li T; Yang Y; Han L
    Int J Nanomedicine; 2020; 15():5839-5853. PubMed ID: 32848393
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reduction Responsive Self-Assembled Nanoparticles Based on Disulfide-Linked Drug-Drug Conjugate with High Drug Loading and Antitumor Efficacy.
    Song Q; Wang X; Wang Y; Liang Y; Zhou Y; Song X; He B; Zhang H; Dai W; Wang X; Zhang Q
    Mol Pharm; 2016 Jan; 13(1):190-201. PubMed ID: 26629710
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced in vitro and in vivo therapeutic efficacy of codrug-loaded nanoparticles against liver cancer.
    Li X; Xu H; Dai X; Zhu Z; Liu B; Lu X
    Int J Nanomedicine; 2012; 7():5183-90. PubMed ID: 23055730
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Folate-modified doxorubicin-loaded nanoparticles for tumor-targeted therapy.
    Wu G; Wang Z; Bian X; Du X; Wei C
    Pharm Biol; 2014 Aug; 52(8):978-82. PubMed ID: 25017652
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel.
    McConathy WJ; Nair MP; Paranjape S; Mooberry L; Lacko AG
    Anticancer Drugs; 2008 Feb; 19(2):183-8. PubMed ID: 18176115
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nanoscaled poly(L-glutamic acid)/doxorubicin-amphiphile complex as pH-responsive drug delivery system for effective treatment of nonsmall cell lung cancer.
    Li M; Song W; Tang Z; Lv S; Lin L; Sun H; Li Q; Yang Y; Hong H; Chen X
    ACS Appl Mater Interfaces; 2013 Mar; 5(5):1781-92. PubMed ID: 23410916
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system.
    Wang L; Wang W; Rui Z; Zhou D
    Drug Deliv; 2016 Nov; 23(9):3200-3208. PubMed ID: 26987435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.